CORONA vs PAR: Stock Comparison

Corona Remedies Ltd vs Par Drugs And Chemicals Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Corona Remedies Ltd is the larger company by market capitalisation. Corona Remedies Ltd shows a higher ROE, a higher dividend yield and faster revenue growth, while Par Drugs And Chemicals Limited shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Corona Remedies Ltd and Par Drugs And Chemicals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CORONA is more favourable on 10 of 13 scored metrics and PAR on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CORONA is the larger company
₹12,934 Cr vs ₹116 Cr
P/E Ratio
PAR has a lower P/E
8.55x vs 69.21x
P/B Ratio
PAR has a lower P/B
0x vs 17.16x
EPS
CORONA has higher earnings per share
₹30.3 vs ₹10.65
Dividend Yield
CORONA has a higher dividend yield
0.49% vs 0%
Revenue Growth (TTM YoY)
CORONA has faster revenue growth
0% vs -12.2%
EPS Growth (TTM YoY)
CORONA has faster EPS growth
0% vs -48.5%
Qtr Sales Growth
CORONA has stronger quarterly sales growth
20.2% vs -12.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCORONAPAR
SectorHealthcare
IndustryPharmaceuticals

Price

MetricCORONAPAR
Live Price₹2,113₹93.79
Day Change4.1%-2.48%
Volume61,59612,063
52-Week High₹2,128.4₹114
52-Week Low₹1,336.6₹78.05
Distance from 52W High-0.72%-17.73%

Valuation

MetricCORONAPAR
Market Cap₹12,934 Cr₹116 Cr
P/E Ratio69.21x8.55x
P/B Ratio17.16x0x
EPS₹30.3₹10.65
Book Value₹122₹90.52
Dividend Yield0.49%0%

Growth

MetricCORONAPAR
Revenue Growth (TTM YoY)0%-12.2%
EPS Growth (TTM YoY)0%-48.5%
Qtr Sales Growth20.2%-12.2%
Qtr Profit Growth43.7%-48.5%

Profitability & Leverage

MetricCORONAPAR
ROE29.5%12.4%
ROCE33.3%16.5%
Net Margin13.19%12.65%
Operating Margin21%16.5%
Debt to Equity0.22x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCORONAPAR
Promoter Holding69%73.41%
FII Holding3.63% 1.38 pp0%
DII Holding12.9% 5.88 pp0.09% 0.09 pp
Public Holding14.48% 7.26 pp26.51% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Corona Remedies Ltd and Par Drugs And Chemicals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.